A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia

Summary

The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.

Eligibility

Inclusion Criteria:

* Age ≥28 days to \<12 years at the time of informed consent/assent.
* Lansky Performance Status (LPS) of ≥ 50%.
* For Phase 1b and Phase 2 cohort in participants with R/R B-ALL:

  * Participants with B-ALL relapsed after or refractory to any line of treatment including allogeneic hematopoietic stem cell transplant (HSCT).
  * Greater than or equal to 5% blasts in the bone marrow (BM) is considered as relapse in the BM.
* For Phase 2 cohort in participants with MRD+ B-ALL:

  * Participants with MRD+ B-ALL must have between ≥ 0.1% and \< 5% blasts in the BM.
* Prior CD19-directed therapy will be allowed (with demonstrated continued CD19+ expression) if treatment ended \>4 weeks prior to start of protocol therapy and no prior central nervous system (CNS) complications.
* Any Philadelphia chromosome-positive (Ph+) participant intolerant or refractory to prior tyrosine kinase inhibitors (TKIs) are eligible.

Exclusion Criteria:

* Active ALL in the CNS.
* History or presence of clinically relevant CNS pathology or event such as epilepsy, childhood seizure, paresis, aphasia, stroke, severe brain injuries, cerebellar disease, organic brain syndrome, psychosis, or severe (≥ grade 3) CNS events including immune effector cell-associated neurologic syndrome (ICANS) from prior CAR-T or other T-cell engager therapies.
* Isolated EM disease.
* Current autoimmune disease or history of autoimmune disease with potential CNS involvement.
* Patients with Down Syndrome are not eligible for this study.
* Active acute or chronic graft versus host disease requiring systemic treatment with immunosuppressive medication.
* Known infection with human immunodeficiency virus (HIV) or chronic infection with hepatitis B virus or hepatitis C virus.
* Presence of an acute or uncontrolled chronic infection, or any other concurrent disease or medical condition that could be worsened by the treatment or interfere with the participant's ability to comply with the study protocol.
* Allogeneic HSCT within 12 weeks before the start of blinatumomab.

Conditions3

Interventions1

Locations3 sites

Find trials near these locations

Related trials

• A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005) — Merck Sharp & Dohme LLC
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia — Mats Heyman
• ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL — Institute of Hematology & Blood Diseases Hospital, China
• Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation — First Affiliated Hospital of Zhejiang University
• Blinatumomab Plus Venetoclax Sequenced With Inotuzumab Ozogamicin in Treating B-ALL — First Affiliated Hospital of Zhejiang University
• Efficacy Study of Blinatumomab Clean Up Early Residual Disease for Newly Diagnosed Pediatric B Lymphoblastic Leukemia — Shanghai Jiao Tong University School of Medicine
• Efficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL — Institute of Hematology & Blood Diseases Hospital, China
• Full-course Immunotherapy Combined With Chemotherapy in Newly Diagnosed B-cell Acute Lymphoblastic Leukemia — The First Affiliated Hospital of Soochow University

Browse More Trials